These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 8623870)

  • 1. Differences in practice patterns between obstetricians and family physicians: use of serum screening.
    Yankowitz J; Howser DM; Ely JW
    Am J Obstet Gynecol; 1996 Apr; 174(4):1361-5. PubMed ID: 8623870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maternal serum screening: practice patterns of physicians in Newfoundland.
    Chandra S; Crane J; Hutchens D; Bennett K; O'Grady T; Duff A; Macgregor D
    J Obstet Gynaecol Can; 2003 Oct; 25(10):825-9. PubMed ID: 14532950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maternal serum triple analyte screening in pregnancy.
    Graves JC; Miller KE; Sellers AD
    Am Fam Physician; 2002 Mar; 65(5):915-20. PubMed ID: 11898965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maternal serum screening.
    Carroll JC
    Can Fam Physician; 1994 Oct; 40():1756-64. PubMed ID: 7524838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maternal serum screening for neural tube defects and fetal chromosome abnormalities.
    Rose NC; Mennuti MT
    West J Med; 1993 Sep; 159(3):312-7. PubMed ID: 7694429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antepartum screening in the office-based practice: findings from the collaborative Ambulatory Research Network.
    Wilkins-Haug L; Horton JA; Cruess DF; Frigoletto FD
    Obstet Gynecol; 1996 Oct; 88(4 Pt 1):483-9. PubMed ID: 8841204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Obstetrical complications associated with abnormal maternal serum markers analytes.
    Gagnon A; Wilson RD;
    J Obstet Gynaecol Can; 2008 Oct; 30(10):918-932. PubMed ID: 19038077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The advantages of using triple-marker screening for chromosomal abnormalities.
    Kellner LH; Weiss RR; Weiner Z; Neuer M; Martin GM; Schulman H; Lipper S
    Am J Obstet Gynecol; 1995 Mar; 172(3):831-6. PubMed ID: 7534448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective evaluation of prenatal maternal serum screening for trisomy 18.
    Yankowitz J; Fulton A; Williamson R; Grant SS; Budelier WT
    Am J Obstet Gynecol; 1998 Mar; 178(3):446-50. PubMed ID: 9539506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Double-positive maternal serum screening results for down syndrome and open neural tube defects: An indicator for fetal structural or chromosomal abnormalities and adverse obstetric outcomes.
    Chitayat D; Farrell SA; Huang T; Meier C; Wyatt PR; Summers AM
    Am J Obstet Gynecol; 2002 Sep; 187(3):758-63. PubMed ID: 12237660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Videotaping obstetric procedures. Assessment of obstetricians and family physicians.
    Eitel DR; Yankowitz J; Ely JW
    Arch Fam Med; 2000 Jan; 9(1):89-91. PubMed ID: 10664650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Maternal serum screening for detection of fetal chromosome abnormalities].
    Holzgreve W; Miny P; Schloo R; Tercanli S
    Gynakologe; 1995 Oct; 28(5):280-8. PubMed ID: 7498824
    [No Abstract]   [Full Text] [Related]  

  • 13. [Maternal serum screening for Down syndrome and neural tube defects].
    van Rijn M; Christiaens GC; van der Schouw YT; Hagenaars AM; de Pater JM; Visser GH
    Ned Tijdschr Geneeskd; 1998 Feb; 142(8):409-15. PubMed ID: 9562776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maternal serum screening for alpha-fetoprotein, unconjugated estriol, and human chorionic gonadotropin between 11 and 15 weeks of pregnancy to detect fetal chromosome abnormalities.
    Crandall BF; Hanson FW; Keener S; Matsumoto M; Miller W
    Am J Obstet Gynecol; 1993 Jun; 168(6 Pt 1):1864-7; discussion 1867-9. PubMed ID: 7686337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 'Dual positivity' for neural tube defects and down syndrome at maternal serum screening: gestational outcome.
    Zanini R; Tarantini M; Cerri V; Jacobello C; Bellotti D; Lancetti S; Scalchi S; Groli C; Bianchi UA
    Fetal Diagn Ther; 1998; 13(2):106-10. PubMed ID: 9650657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prenatal screening using maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol: two-year experience in a health maintenance organization.
    McDuffie RS; Haverkamp AD; Stark CF; Haverkamp C; Barth CK
    J Matern Fetal Med; 1996; 5(2):70-3. PubMed ID: 8796771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening for Down syndrome: practice patterns and knowledge of obstetricians and gynecologists.
    Cleary-Goldman J; Morgan MA; Malone FD; Robinson JN; D'Alton ME; Schulkin J
    Obstet Gynecol; 2006 Jan; 107(1):11-7. PubMed ID: 16394034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second trimester serum predictors of congenital heart defects in pregnancies without chromosomal or neural tube defects.
    Jelliffe-Pawlowski L; Baer R; Moon-Grady AJ; Currier RJ
    Prenat Diagn; 2011 May; 31(5):466-72. PubMed ID: 21351282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Down syndrome and neural tube defect screening: the value of using gestational age by ultrasonography.
    Benn PA; Borgida A; Horne D; Briganti S; Collins R; Rodis JF
    Am J Obstet Gynecol; 1997 May; 176(5):1056-61. PubMed ID: 9166168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Serum marker screening during the second trimester for prenatal diagnosis and predicting pregnancy outcome].
    Yang L; Zhao L; Jiang J; Liu J; Tao H; Wang J; Wu J
    Nan Fang Yi Ke Da Xue Xue Bao; 2015 Jul; 35(7):1059-62, 1072. PubMed ID: 26198962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.